GIP and Insulin resistance: In another preclinical study, GE demonstrated superior metabolic effects compared to GLP-1-GIP or GLP-1-GIP-glucagon multiagonist therapies in models of polycystic ovary syndrome (PCOS), a condition frequently associated with obesity and insulin resistance.